Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg) is a pharmaceutical drug with 7 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
1
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
2
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours
Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging
Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users
Tenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial
Clinical Trials (7)
Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours
Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging
Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users
Tenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial
Safety Of A Second Dose Of Tenecteplase In Selected Acute Ischemic Stroke Patients Not Responding To The First Dose
Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7